Anna Tempesta , Anna Tolomeo , Azzurra Stefanucci , Lorenza Marinaccio , Adriano Mollica
{"title":"使用放射性药物诊断神经退行性疾病","authors":"Anna Tempesta , Anna Tolomeo , Azzurra Stefanucci , Lorenza Marinaccio , Adriano Mollica","doi":"10.1016/j.ejmcr.2024.100239","DOIUrl":null,"url":null,"abstract":"<div><div>Neurodegenerative diseases are illnesses that affect the central nervous system (CNS) characterized by a series of symptoms such as dementia, motor disturbances, behavioural and psychological disorders, and cognitive impairments. The most common neurodegenerative disorders are Alzheimer's disease and Parkinson's disease, for which radiopharmaceuticals have been developed and approved for the purpose of PET investigation. Biomarkers are molecules that can be studied and used for diagnostic purposes, to monitor diseases, and to identify potential risk factors early.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"12 ","pages":"Article 100239"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of radiopharmaceuticals in the diagnosis of neurodegenerative diseases\",\"authors\":\"Anna Tempesta , Anna Tolomeo , Azzurra Stefanucci , Lorenza Marinaccio , Adriano Mollica\",\"doi\":\"10.1016/j.ejmcr.2024.100239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Neurodegenerative diseases are illnesses that affect the central nervous system (CNS) characterized by a series of symptoms such as dementia, motor disturbances, behavioural and psychological disorders, and cognitive impairments. The most common neurodegenerative disorders are Alzheimer's disease and Parkinson's disease, for which radiopharmaceuticals have been developed and approved for the purpose of PET investigation. Biomarkers are molecules that can be studied and used for diagnostic purposes, to monitor diseases, and to identify potential risk factors early.</div></div>\",\"PeriodicalId\":12015,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry Reports\",\"volume\":\"12 \",\"pages\":\"Article 100239\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772417424001110\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772417424001110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
神经退行性疾病是一种影响中枢神经系统（CNS）的疾病，以痴呆、运动障碍、行为和心理障碍以及认知障碍等一系列症状为特征。最常见的神经退行性疾病是阿尔茨海默病和帕金森病，针对这两种疾病开发的放射性药物已被批准用于 PET 研究。生物标记物是可以研究和用于诊断目的、监测疾病和早期识别潜在风险因素的分子。
Use of radiopharmaceuticals in the diagnosis of neurodegenerative diseases
Neurodegenerative diseases are illnesses that affect the central nervous system (CNS) characterized by a series of symptoms such as dementia, motor disturbances, behavioural and psychological disorders, and cognitive impairments. The most common neurodegenerative disorders are Alzheimer's disease and Parkinson's disease, for which radiopharmaceuticals have been developed and approved for the purpose of PET investigation. Biomarkers are molecules that can be studied and used for diagnostic purposes, to monitor diseases, and to identify potential risk factors early.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
